ABSTRACT
ABSTRACT
Over 50% of all medicines given to children (and some 90% of those given to the newly-born) have never been tested or authorised for use on them. The European Commission want to stimulate the development of medicines for children and lay down rules for testing and approval. It is high time this was done and the framework proposed seems right. But ethical considerations on the implementation of the rules need to be carefully considered and the incentive mechanisms proposed are a leap of faith which will have to be examined rigorously after they have been tried out.
|
|
|
